The United States Patent and Trademark Office (USPTO) announced today the finalized fee increases taking effect on January 19, 2025. While applicants can still expect significant increases in certain areas, some proposed fee increases were not implemented following pushback from public commentators. One notable example relates to terminal disclaimers. The USPTO had proposed a tiered
RF EMerge
A Resource for Innovators
Blog Authors
Latest from RF EMerge
Key Inventorship Considerations in AI-assisted Drug Development
The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is no exception.
AI-driven platforms have become increasingly useful to biotech innovators in many areas including in discovering and developing drugs. For example, a 2022 article by McKinsey & Company estimated that nearly 270 companies have…
The Future of Food: Regulatory and Patent Landscape of Genome Editing in Food Technology
Our current food system is facing a myriad of critical challenges. The United Nations predicts that the world population will reach 9.3 billion people by 2050, which means that we will need to produce 60% more food to feed the world in the next decades.[1] Current food production processes are not up to the…
The Corporate Transparency Act: What you Need to Know to Comply with the New Requirements
The Corporate Transparency Act (CTA) went into effect on January 1, 2024, and will impact millions of U.S. businesses by imposing requirements to file corporate transparency reports with beneficial ownership information (“BOI”) before January 1, 2025. Here, we summarize some key points and remind business owners to comply with these new requirements as soon as possible…
Meating of the Minds: Impossible Foods and Motif Foodworks Settle High Profile Patent Dispute in District Court
The food tech industry has been growing and evolving rapidly in the last ten years due to technological innovations in the space and a growing customer demand for plant-based food products and sustainable meat options. We have previously covered a high profile legal battle in the plant-based meat sector of this industry discussing (1) t…
Advanced IP Considerations for Cell-and-Gene Therapeutic Companies Utilizing Lipid Nanoparticle Delivery Systems
As I have written about previously, the IP and competitive landscape for mRNA and lipid nanoparticles is complex. Pioneers, mid-stage, and new market entrants must take careful consideration of this landscape and develop a strategy to best position their businesses in this evolving space. This post provides an analytical framework for advanced IP considerations to…
This Summer in Artificial Intelligence: Newly Released USPTO Guidance and Exemplary Worldwide Inventorship Updates
The Unted States Patent and Trademark Office (USPTO) recently published new guidance on subject-matter eligibility as related to Artificial Intelligence (AI), opening a written comment window to respond with a deadline of September 16, 2024. The guidance was brought about by an October 2023 Executive Order on the “Safe, Secure, and Trustworthy Development and…
USPTO Fees Are Rising Drastically in 2025: What to Do Now to Save Thousands of Dollars
Heading into 2025, patent applicants should prepare for significant fee increases at the United States Patent and Trademark Office (USPTO). These fee increases can significantly impact patent applicant behavior, leading prudent applicants to evaluate and adjust their patent protection strategies. Pharmaceutical and biotechnology companies in particular should plan and budget for new and drastically increased…
Client Spotlight: BASE Air Management
BASE Air is a company at the leading edge of safety in the heavy vehicle industry. Founded in 2005 by Matthew Vaughan in Australia, the company focuses on Balance and Safety Enhancement (BASE) for heavy-duty vehicle stability. BASE Air’s technology is a pressure-control system capable of integrating into a vehicle’s existing air suspension, or available…
Gene Therapy Approvals Gain Steam in 2023: FDA Approves First Gene Therapies for Sickle Cell Disease
In a long-awaited milestone in the gene therapy space, the Food and Drug Administration (FDA) approved two gene therapies to cure sickle cell disease (SCD). Soon thereafter these approvals, a key licensing agreement was announced between Vertex and Editas for Cas9 gene editing technology.
Gene therapy is a new type of treatment with the potential…